Direction of Market Influences: Special Research on Polypore, Valeant, Apple, 3M, and Bristol-Myers
NEW YORK, February 24, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Polypore (NYSE: PPO), Valeant (NYSE: VRX), Apple (NASDAQ: AAPL), 3M (NYSE: MMM), and Bristol-Myers (NYSE:BMY). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
PPO Research Report: ( http://get.analystsreview.com/pdf/?c=Polypore&d=24-Feb-2015&s=PPO ),
VRX Research Report: ( http://get.analystsreview.com/pdf/?c=Valeant&d=24-Feb-2015&s=VRX ),
AAPL Research Report: ( http://get.analystsreview.com/pdf/?c=Apple&d=24-Feb-2015&s=AAPL ),
MMM Research Report: ( http://get.analystsreview.com/pdf/?c=3M&d=24-Feb-2015&s=MMM ),
BMY Research Report: ( http://get.analystsreview.com/pdf/?c=Bristol-Myers&d=24-Feb-2015&s=BMY ).
============
--
Analyst Update: Sale Agreements,Collaboration and Acquisitions Deals
Reviewed by: Rohit Tuli, CFA®
U.S. stock markets witnessed a mixed trend on Monday, as the indices pulled back from records reached last week. The Dow Jones Industrial Average fell 23.6 points, or 0.1%, to 18116.84. The S&P 500 lost 0.64 point to 2109.66, while the Nasdaq Composite added 5.01 points, or 0.1%, to 4960.97. Falling oil prices and disappointing data on US existing home sales weighed upon the markets. However, European stocks rallied after Greek creditors agreed to extend the nation's bailout funds. The Stoxx Europe 600 Index added 0.7% to 385.08 at the close in London. Asian markets were mostly up on Monday, buoyed by a bailout deal between Greece and the euro zone last week. Japan's key Nikkei 225 index jumped 0.7% and Australia's benchmark S&P ASX 200 index gained 0.5%. Trading volumes remained light with China, Taiwan and Vietnam still closed for the Chinese New Year holiday.
Polypore International, Inc.'s (Polypore) stock shot up almost 13% yesterday after the Company agreed to be acquired by Asahi Kasei, a Japanese chemical company, for $60.50 per share in cash. To read more on the deal and management's view, visit our research report on Polypore.
Shares of Valeant Pharmaceuticals International Inc. (Valeant) surged 14.71% to close Monday's session at $198.75 after the Company announced that it has agreed to acquire all of the outstanding common stock of Salix Pharmaceuticals ltd for $158.00 per share in cash, or a total enterprise value of approximately $14.5 billion. The transaction is expected to be over 20% accretive to Cash EPS in 2016. To read more on the deal and financial results, visit our research report on Valeant.
Apple on Monday announced plans to invest €1.7 billion in two new European data centres, each powered by 100% renewable energy. The new investment represents Apple's biggest project in Europe to date. The facilities will be located in County Galway, Ireland, and Denmark's central Jutland. Apple's CEO Tim Cook said that he is thrilled to be expanding operations, creating hundreds of local jobs and introducing some of its most advanced green building designs yet. Know in depth about the Investment by reading our Research Report on Apple.
Shares of 3M Co. (3M) ended Monday's trading at $168.81, up 0.41% following reports that the Company has signed an agreement with Polypore International Inc. to acquire Polypore's Separations Media business, complementing its Core Filtration Technologies Platform. Know more about 3M's acquisition deal in our research report.
Shares of Bristol-Myers Squibb Co. (Bristol-Myers) gained 1.27% to end Monday's trading at $61.29 following reports that the Company has signed an acquisition deal Flexus Biosciences, Inc., to expand its Immuno-Oncology Pipeline. The Company also announced its R&D collaboration with Rigel Pharmaceuticals, Inc. for TGF Beta Receptor Kinase inhibitors for use in Immuno-Oncology related indications. Continue reading about Bristol-Myers's recent deals and collaboration to strengthen Immuno-Oncology pipeline in our research report.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article